Newton's Neurolens N3 Gains CE Marking for EU Medical Devices, Revolutionizing Eye Care

On November 17, 2026, Newton, Inc., an eye care technology firm based in Dallas, proudly announced the receipt of the CE marking for its Neurolens N3 under the EU Medical Device Regulations (MDR). This recognition signifies a pivotal moment for eye care professionals across Europe, enabling them to provide patients with an effective, clinically validated, and drug-free approach to alleviate symptoms such as headaches, neck and shoulder pain, and motion sickness related to ocular misalignment.

The CE marking allows for the introduction of Neurolens across 30 European countries, where eye care professionals will now be able to conduct objective measurements of ocular alignment during eye examinations. This is a significant advancement considering a recent survey involving over 8,000 adults across nine European nations revealed that nearly 80% had encountered headaches in the past year, underscoring the urgent need for effective treatment options in the region.

Davis Corley, the CEO of Newton, expressed the importance of this achievement, stating, "CE marking under the MDR is a defining milestone for Newton. It reflects the rigor behind our technology and our team, and it opens the door for eye care professionals across Europe to offer their patients a new answer to symptoms they've often lived with for years."

The rigorous requirements established under the EU MDR ensure that medical devices meet elevated standards in terms of clinical evidence, quality management, and post-market surveillance. Newton's successful certification signifies not only its commitment to product excellence but also its aspiration for international growth.

The Neurolens N3 utilizes advanced eye-tracking technology to deliver objective measurements of eye alignment, a crucial step in prescribing the innovative Contoured Prism™ lenses of Neurolens. The lens has been clinically proven to substantially reduce the daily impact of headaches. A clinical trial highlighted in "Translational Vision Science & Technology" reported patients achieving an average reduction in their headache impact scores after four weeks of using Neurolens.

As the N3 enters the market, eye care professionals can effectively incorporate its streamlined, staff-friendly workflow into the pre-test routine, allowing for quick and accurate alignment assessments. Patients can expect a significant reduction in symptoms associated with ocular misalignment, as numerous users have reported noticeable improvements within just 60 days of wear.

"Achieving EU MDR certification is a major step forward for Newton," noted Gregory Boisse, Sr. VP of Operations and R&D. "It reflects the hard work and discipline our team brings to every stage of our product development, from research and clinical evaluation to quality and manufacturing. I'm incredibly proud of the people behind this achievement and excited for what it means for our future."

Looking ahead, Newton anticipates launching Neurolens to its initial European markets in 2027, further extending its reach beyond existing markets in the United States and Canada. This expansion underscores Newton’s mission to enhance patient care through innovative eye care solutions.

Based in Dallas, Newton, Inc. is committed to empowering eye care professionals with cutting-edge technology. Its offerings, including the clinically substantial Neurolens equipped with Contoured Prism™ technology and Sequel™ with Convergence Boost™, affirm its dedication to improving patient outcomes. To date, Neurolens technology has facilitated over 4 million eye alignment measurements, benefitting over 350,000 patients across North America.

For more information, visit www.newton.tech.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.